3 September 2021 - supply agreement

The AIM-quoted pharmaceutical services and products company has announced a new distribution agreement with PAION AG, a German pharmaceutical group which specialises in anesthesia and critical care services. The latter's main product is remimazolam, a sedative/anesthetic marketed under the brand name Byfavo.  Clinigen has been granted exclusive distribution rights for the UK and other products may follow.  Shares in Clinigen have languished around the current level for some time although any move above 640p would be a bullish sign and the shares have flirted with this level a couple of times recently . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.